| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 158: 503-510 (1991)
© 1991 The Royal College of Psychiatrists
JA Lieberman, BL Saltz, CA Johns, S Pollack, M Borenstein and J Kane
Hillside Hospital, Glen Oaks, New York.
This article reviews eight published studies that describe clozapine's effects on TD and examines the outcome of 30 patients with TD treated with clozapine for up to 36 months. These data indicate that TD response to clozapine is variable but that approximately 43% of cases, particularly those with dystonic features, improved after clozapine treatment. Methodological limitations of the studies described, however, preclude definitive conclusions, which must await appropriately controlled trials.
This article has been cited by other articles:
|
|
 |
|
  S. Kumra, J. V. Oberstar, L. Sikich, R. L. Findling, J. M. McClellan, S. Vinogradov, and S. Charles Schulz Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia Schizophr Bull, January 1, 2008; 34(1): 60 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
 |
|
 J. M. Noel ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Weiden Switching antipsychotics: an updated review with a focus on quetiapine J Psychopharmacol, January 1, 2006; 20(1): 104 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 C. U. Correll, S. Leucht, and J. M. Kane Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Am J Psychiatry, March 1, 2004; 161(3): 414 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Bressan, H. M. Jones, and L. S. Pilowsky Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity J Psychopharmacol, March 1, 2004; 18(1): 124 - 127. [Abstract] [PDF]
|
|
|
|
 |
|
 L. H. Beebe Health Promotion in Persons with Schizophrenia: Atypical Medications Journal of the American Psychiatric Nurses Association, August 1, 2003; 9(4): 115 - 122. [Abstract] [PDF]
|
|
|
|
|
|
D. V. Jeste, A. Okamoto, J. Napolitano, J. M. Kane, and R. A. Martinez Low Incidence of Persistent Tardive Dyskinesia in Elderly Patients With Dementia Treated With Risperidone Am J Psychiatry, July 1, 2000; 157(7): 1150 - 1155. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. H. Littrell, C. G. Johnson, S. Littrell, and C. D. Peabody Marked Reduction of Tardive Dyskinesia With Olanzapine Arch Gen Psychiatry, March 1, 1998; 55(3): 279 - 280. [Full Text] [PDF]
|
|
|
|
 |
|
 The drug treatment of patients with schizophrenia DTB, November 1, 1995; 33(11): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
